Sodium glycolate, 98%

Synonyms: 乙醇酸钠,98%; Sodium hydroxyacetate, 98%
Sodium glycolate, 98% (Sodium hydroxyacetate, 98%) 是一种具有口服活性且用途广泛的有机盐,作为酶活性调节剂可提高乙醇酸氧化酶 (GAO) 和乳酸脱氢酶 (LDH) 活性、降低乙醇酸脱氢酶 (GAD) 活性,可在大鼠体内诱导草酸盐生物合成并引发高草酸尿症,还能降低雄性白化病大鼠的尿钙排泄量,因此可用于草酸钙尿结石形成及高草酸尿症的相关研究。
产品编号: MS-Y88810 纯度: 98.0% CAS No.: 2836-32-0 分子式: C2H3NaO3 分子量: 98.03
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in Water
询价
3-5 天
10g
询价
3-5 天
25g
询价
3-5 天
50g
询价
3-5 天
> 100g
询价
询价

产品描述

Sodium glycolate, 98% (Sodium hydroxyacetate, 98%) 是一种具有口服活性且用途广泛的有机盐,作为酶活性调节剂可提高乙醇酸氧化酶 (GAO) 和乳酸脱氢酶 (LDH) 活性、降低乙醇酸脱氢酶 (GAD) 活性,可在大鼠体内诱导草酸盐生物合成并引发高草酸尿症,还能降低雄性白化病大鼠的尿钙排泄量,因此可用于草酸钙尿结石形成及高草酸尿症的相关研究。

生物实验数据

生物活性 Sodium glycolate, 98% (Sodium hydroxyacetate, 98%) is an orally active and versatile organic salt that acts as an enzyme activity modulator by increasing glycolate oxidase (GAO) and lactate dehydrogenase (LDH) activities while decreasing glycolate dehydrogenase (GAD) activity, induces oxalate biosynthesis and elicits hyperoxaluria in rats, reduces urinary calcium excretion in male albino rats, and can therefore be used in research related to calcium oxalate urolithiasis formation and hyperoxaluria.
体内研究
(In Vivo)

Sodium glycolate (50 mg/100 g 体重/天;口服;每日;连续 7 天) 相较于成年雄性 Wistar 大鼠的正常对照组,可显著提升肝脏 GAO 及肝/肾 LDH 活性,显著降低肝脏蛋白含量、肾脏蛋白含量与肾脏 GAD 活性,还会定向降低肝脏 GAD 活性并增加肝脏重量。
Sodium glycolate, 98% (100 mg/100 g 体重/天;口服;每日给药;持续 6 周) 可在雄性 Wistar 大鼠中诱导显著的高草酸尿症,同时伴随低钙尿症以及肝脏、肾脏和红细胞中转氨酶活性降低。
Sodium glycolate, 98% (100 mg/100 g 体重/天;口服;每日给药;持续 6 周) 与吡哆醇联合给药可在雄性 Wistar 大鼠中诱导显著的高草酸尿症,同时相较于仅用乙醇酸钠处理的大鼠,还会出现低钙尿症、尿柠檬酸排泄增加以及肾脏转氨酶活性部分恢复的现象。

Animal Model: Wistar (male, 4 months old)
Dosage: 50 mg/100 g body weight/day
Administration: p.o.; daily; 7 days
Result: Significantly increased liver weight relative to normal controls.
Significantly increased liver weight/100 g body weight relative to normal controls.
Significantly lowered liver protein to 174 mg/g relative to normal controls.
Did not significantly change kidney weight and kidney weight/100 g body weight relative to normal controls.
Significantly lowered kidney protein to 212 mg/g relative to normal controls.
Significantly increased liver LDH activity to 3.71 U/mg protein relative to normal controls.
Significantly increased liver GAO activity to 1.33 U/mg protein relative to normal controls.
Directionally reduced liver GAD activity to 1.86 × 10-2 U/mg protein, with no statistically significant difference relative to normal controls.
Significantly increased kidney LDH activity to 3.67 U/mg protein relative to normal controls.
Significantly reduced kidney GAD activity to 0.18 × 10-2 U/mg protein relative to normal controls.
Animal Model: Wistar (male, 200 g body weight)
Dosage: 100 mg per 100 g body weight/24 hr
Administration: p.o.; daily; 6 weeks
Result: Increased urinary oxalate levels to 55 mg/dg creatinine at week 1, 36 mg/dg creatinine at week 2, 44 mg/dg creatinine at week 4, and 36 mg/dg creatinine at week 5, compared to a basal level of 19 mg/dg creatinine.
Decreased urinary calcium excretion to 37 mg/dg creatinine at week 1, 14 mg/dg creatinine at week 3, 35 mg/dg creatinine at week 4, 18 mg/dg creatinine at week 5, and 35 mg/dg creatinine at week 6, compared to a basal level of 100 mg/dg creatinine.
Reduced liver glutamate-oxaloacetate transaminase (GOT) activity to 8.29 μmoles pyruvate produced/min/mg protein × 10-2.
Reduced kidney GOT activity to 6.06 μmoles pyruvate produced/min/mg protein × 10-2 and kidney glutamate-pyruvate transaminase (GPT) activity to 0.37 μmoles pyruvate produced/min/mg protein × 10-2.
Reduced erythrocyte GOT activity to 0.29 μmoles pyruvate produced/min/mg protein × 10-2.
Caused a slight, insignificant increase in body weight (from 199 g to 242 g) over 6 weeks, with no significant changes in liver weight (5.7 g), kidney weight (1.6 g), liver protein content (159 mg/g tissue), or kidney protein content (154 mg/g tissue) relative to pyridoxine-supplemented sodium glycolate-treated rats.
Animal Model: Wistar (male, 200 g body weight)
Dosage: 100 mg per 100 g body weight/24 hr (sodium glycolate); 10 mg per 100 g body weight/24 hr (pyridoxine)
Administration: p.o.; daily; 6 weeks
Result: Increased urinary oxalate levels to 50 mg/dg creatinine at week 1, 30 mg/dg creatinine at week 2, and 32 mg/dg creatinine at week 4, compared to a basal level of 19 mg/dg creatinine.
Decreased urinary calcium excretion to 22 mg/dg creatinine at week 1, 26 mg/dg creatinine at week 3, 32 mg/dg creatinine at week 4, 26 mg/dg creatinine at week 5, and 32 mg/dg creatinine at week 6, compared to a basal level of 100 mg/dg creatinine.
Increased urinary citrate excretion to 372 mg/dg creatinine at week 2, 369 mg/dg creatinine at week 3, and 466 mg/dg creatinine at week 6, compared to a basal level of 227 mg/dg creatinine.
Caused a slight, insignificant increase in body weight (from 185 g to 245 g) over 6 weeks, with no significant changes in liver weight (5.9 g), kidney weight (1.6 g), liver protein content (191 mg/g tissue), or kidney protein content (151 mg/g tissue) relative to sodium glycolate-only treated rats.
性状 固体
颜色 White to off-white

化学信息

分子量 98.03
分子式 C2H3NaO3
CAS No. 2836-32-0
别名 乙醇酸钠,98%; Sodium hydroxyacetate, 98%

储存&溶解度

储存方式

4°C, stored under nitrogen, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : ≥ 100 mg/mL (1020.10 mM)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM10.2010 mL51.0048 mL102.0096 mL255.0240 mL
5 mM2.0402 mL10.2010 mL20.4019 mL51.0048 mL
10 mM1.0201 mL5.1005 mL10.2010 mL25.5024 mL
15 mM0.6801 mL3.4003 mL6.8006 mL17.0016 mL
20 mM0.5100 mL2.5502 mL5.1005 mL12.7512 mL
25 mM0.4080 mL2.0402 mL4.0804 mL10.2010 mL
30 mM0.3400 mL1.7002 mL3.4003 mL8.5008 mL
40 mM0.2550 mL1.2751 mL2.5502 mL6.3756 mL
50 mM0.2040 mL1.0201 mL2.0402 mL5.1005 mL
60 mM0.1700 mL0.8501 mL1.7002 mL4.2504 mL
80 mM0.1275 mL0.6376 mL1.2751 mL3.1878 mL
100 mM0.1020 mL0.5100 mL1.0201 mL2.5502 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础